Inbal Shafran

580 total citations
17 papers, 343 citations indexed

About

Inbal Shafran is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Immunology. According to data from OpenAlex, Inbal Shafran has authored 17 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in Cardiology and Cardiovascular Medicine and 4 papers in Immunology. Recurrent topics in Inbal Shafran's work include Pulmonary Hypertension Research and Treatments (6 papers), COVID-19 Clinical Research Studies (3 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Inbal Shafran is often cited by papers focused on Pulmonary Hypertension Research and Treatments (6 papers), COVID-19 Clinical Research Studies (3 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Inbal Shafran collaborates with scholars based in Austria, Israel and United States. Inbal Shafran's co-authors include Amir Shlomai, Noa Shafran, Liron Sheena, Ella H. Sklan, Haim Ben‐Zvi, Ilan Krause, Elad Goldberg, Iréne Lang, Bernhard Moser and Walter Klepetko and has published in prestigious journals such as Blood, Scientific Reports and European Heart Journal.

In The Last Decade

Inbal Shafran

14 papers receiving 337 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Inbal Shafran Austria 8 89 87 76 65 65 17 343
Stefan Hatzl Austria 14 49 0.6× 43 0.5× 225 3.0× 150 2.3× 162 2.5× 44 525
Knut Anders Mosevoll Norway 13 109 1.2× 31 0.4× 42 0.6× 122 1.9× 86 1.3× 25 456
Hongxia Li China 11 77 0.9× 73 0.8× 35 0.5× 106 1.6× 28 0.4× 33 291
Christophe Langouët-Astrié United States 9 30 0.3× 38 0.4× 107 1.4× 113 1.7× 42 0.6× 19 313
Katherina Aguilera Sweden 4 131 1.5× 32 0.4× 205 2.7× 151 2.3× 30 0.5× 7 350
Yasutsugu Fukushima Japan 13 87 1.0× 184 2.1× 17 0.2× 38 0.6× 73 1.1× 44 416
Cansu Yanginlar Netherlands 9 301 3.4× 73 0.8× 145 1.9× 202 3.1× 65 1.0× 10 614
Nonantzin Beristain‐Covarrubias United Kingdom 6 68 0.8× 16 0.2× 47 0.6× 29 0.4× 25 0.4× 9 219
Kari V. Lunsford United States 11 57 0.6× 68 0.8× 14 0.2× 31 0.5× 72 1.1× 14 347
Haixia Kang China 4 157 1.8× 35 0.4× 41 0.5× 210 3.2× 66 1.0× 4 358

Countries citing papers authored by Inbal Shafran

Since Specialization
Citations

This map shows the geographic impact of Inbal Shafran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inbal Shafran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inbal Shafran more than expected).

Fields of papers citing papers by Inbal Shafran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inbal Shafran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inbal Shafran. The network helps show where Inbal Shafran may publish in the future.

Co-authorship network of co-authors of Inbal Shafran

This figure shows the co-authorship network connecting the top 25 collaborators of Inbal Shafran. A scholar is included among the top collaborators of Inbal Shafran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inbal Shafran. Inbal Shafran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Huszti, Ella, Michael Peled, Tammy Hod, et al.. (2024). Referral rates and barriers to lung transplantation based on pulmonary function criteria in interstitial lung diseases: a retrospective cohort study. Therapeutic Advances in Respiratory Disease. 18. 2683801078–2683801078. 1 indexed citations
3.
Shafran, Inbal, Adelheid Panzenböck, Roela Sadushi‐Kolici, et al.. (2024). Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension. JACC Heart Failure. 12(6). 1089–1097. 2 indexed citations
4.
Voigt, Wieland, et al.. (2023). Changes in tidal breathing biomarkers as indicators of treatment response in AECOPD patients in an acute care setting. Advances in Medical Sciences. 68(2). 176–185.
5.
Mandelboim, Michal, Neta S. Zuckerman, Ana Belkin, et al.. (2023). Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia in Patients Treated With Anti-CD20 Monoclonal Antibodies. Open Forum Infectious Diseases. 10(10). ofad464–ofad464. 4 indexed citations
6.
Hu, Jiun‐Ruey, Shuang Huang, Adelheid Panzenboeck, et al.. (2022). The prognostic value of vasoresponse to nitric oxide in patients with chronic thromboembolic pulmonary hypertension. European Heart Journal. 43(Supplement_2).
7.
Shafran, Noa, Assaf Issachar, Tzippy Shochat, et al.. (2021). Abnormal liver tests in patients with SARS-CoV-2 or influenza – prognostic similarities and temporal disparities. JHEP Reports. 3(3). 100258–100258. 21 indexed citations
8.
Rosta, Klára, Herbert Kiss, Péter Mandl, et al.. (2021). Vaginal microbiota in pregnant women with inflammatory rheumatic and inflammatory bowel disease: A matched case‐control study. Mycoses. 64(8). 909–917. 7 indexed citations
9.
Shafran, Noa, Inbal Shafran, Haim Ben‐Zvi, et al.. (2021). Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Scientific Reports. 11(1). 12703–12703. 121 indexed citations
10.
Gerges, Christian, Mario Gerges, Inbal Shafran, et al.. (2021). Efficacy and Safety of Percutaneous Pulmonary Artery Subtotal Occlusion and Chronic Total Occlusion Intervention in Chronic Thromboembolic Pulmonary Hypertension. Circulation Cardiovascular Interventions. 14(8). e010243–e010243. 31 indexed citations
11.
Gerges, Christian, Inbal Shafran, Roela Sadushi‐Kolici, et al.. (2021). Efficacy and safety of percutaneous pulmonary artery subtotal occlusion and CTO intervention in chronic thromboembolic pulmonary hypertension. European Heart Journal. 42(Supplement_1). 1 indexed citations
12.
Sharma, Smriti, Thomas M. Hofbauer, Anna S. Ondracek, et al.. (2020). Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis. Blood. 137(8). 1104–1116. 110 indexed citations
13.
Shafran, Inbal, Farideh Alasti, Josef S Smolen, & Daniel Aletaha. (2020). Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Annals of the Rheumatic Diseases. 79(7). 874–882. 14 indexed citations
14.
Shafran, Inbal, Vincent Probst, Roela Sadushi‐Kolici, et al.. (2020). The role of asymmetric dimethylarginine (ADMA) in the follow-up of patients with precapillary pulmonary hypertension (PH). European Heart Journal. 41(Supplement_2). 3 indexed citations
15.
Stemmer, Amos, Inbal Shafran, Salomon M. Stemmer, & Daliah Tsoref. (2020). Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. Cancers. 12(10). 3026–3026. 10 indexed citations
16.
Sadushi‐Kolici, Roela, et al.. (2019). Iron Deficiency in Chronic Thromboembolic Pulmonary Hypertension. PA1443–PA1443. 1 indexed citations
17.
Shafran, Inbal, Gahl Greenberg, Ehud Grossman, & Avshalom Leibowitz. (2016). Diabetic striatopathy—Does it exist in non-Asian subjects?. European Journal of Internal Medicine. 35. 51–54. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Hatzl Breakdown of academic impact, for papers by Knut Anders Mosevoll Breakdown of academic impact, for papers by Hongxia Li Breakdown of academic impact, for papers by Christophe Langouët-Astrié Breakdown of academic impact, for papers by Katherina Aguilera Breakdown of academic impact, for papers by Yasutsugu Fukushima Breakdown of academic impact, for papers by Cansu Yanginlar Breakdown of academic impact, for papers by Nonantzin Beristain‐Covarrubias Breakdown of academic impact, for papers by Kari V. Lunsford Breakdown of academic impact, for papers by Haixia Kang
Rankless by CCL
2026